Presentations from the eighth WFH Global Forum
September 26-27, 2013


The safety and sustainability of plasma product

Thomas R. Kreil, Baxter BioScience
New Technologies for Virus Testing: Where Donor Screening is going. Presentation  

J. Michael Soucie, Centers for Disease Control and Prevention
Transmission of B19 and hepatitis E by plasma products. Presentation  

Johannes Bluemel, Paul-Ehrlich-Institut
Viral inactivation on non-lipid viruses such as parvovirus B19 and hepatitis E. Presentation 

Point/counterpoint – the future of plasma is bright versus who will need it when recombinant costs drop significantly?

Magdy El Ekiaby, Shabrawichi Hospital
Pessimistic on plasma. Presentation

Pierre-François Falcou, LFB Biomedicaments
Optimistic on plasma. Presentation

The clinical and economic aspects of novel treatment products

Marilyn Manco-Johnson, The University of Colorado Hemophilia & Thrombosis Center
Is the annual bleed rate enough? The micropathology of joints. Presentation  

Albert Farrugia, Plasma Protein Therapeutics Association
Economic considerations – pricing, sustainability, access, increased supply? Presentation

Mark W. Skinner, WFH USA
Patient perspective. Presentation


Product choice – what does it mean?

Panel discussion: What do we mean by “product choice”?

Brian O’Mahony, European Haemophilia Consortium
Product choice – what does it mean?  Presentation

The impact of regulatory factors on product access

Flora Peyvandi, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
Orphan designation and market exclusivity. Presentation 

Jerry S. Powell, Hemostasis and Thrombosis Center of University of California at Davis
Market Exclusivity for Haemophilia Products. Presentation 

Marijke van den Berg, Department of Health Science and Epidemiology - University Hospital of Utrecht
Interchangeability of Coagulations proteins: The treaters perspective. Presentation

Manufacturer updates

Mathias Juers, CSL Behring
Coagulation research. Presentation

Updated November 2013